Literature DB >> 32741476

Advances in the Imaging of Pituitary Tumors.

James MacFarlane1, Waiel A Bashari1, Russell Senanayake1, Daniel Gillett2, Merel van der Meulen1, Andrew S Powlson1, Angelos Kolias3, Olympia Koulouri1, Mark Gurnell4.   

Abstract

In most patients with pituitary adenomas magnetic resonance imaging (MRI) is essential to guide effective decision-making. T1- and T2-weighted sequences allow the majority of adenomas to be readily identified. Supplementary MR sequences (e.g. FLAIR; MR angiography) may also help inform surgery. However, in some patients MRI findings are 'negative' or equivocal (e.g. with failure to reliably identify a microadenoma or to distinguish postoperative change from residual/recurrent disease). Molecular imaging [e.g. 11C-methionine PET/CT coregistered with volumetric MRI (Met-PET/MRCR)] may allow accurate localisation of the site of de novo or persistent disease to guide definitive treatment (e.g. surgery or radiosurgery).
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (11)C-methionine; MRI; Met-PET/MR(CR); PET/CT; Pituitary adenoma

Mesh:

Year:  2020        PMID: 32741476     DOI: 10.1016/j.ecl.2020.06.002

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  3 in total

Review 1.  Consensus on diagnosis and management of Cushing's disease: a guideline update.

Authors:  Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller
Journal:  Lancet Diabetes Endocrinol       Date:  2021-10-20       Impact factor: 32.069

2.  Pituitary tumor centers of excellence for Cushing's disease.

Authors:  Marcos Couselo; Stefano Frara; Andrea Giustina; Felipe F Casanueva
Journal:  Pituitary       Date:  2022-09-10       Impact factor: 3.599

3.  Costs and Its Determinants in Pituitary Tumour Surgery.

Authors:  Alies J Dekkers; Friso de Vries; Amir H Zamanipoor Najafabadi; Emmy M van der Hoeven; Marco J T Verstegen; Alberto M Pereira; Wouter R van Furth; Nienke R Biermasz
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-07       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.